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Abstract
The transcription factor NURR1 regulates the dopamine (DA) signaling pathway and exerts a critical role in the
development of midbrain dopaminergic neurons (mDA). NURR1 alterations have been linked to DA-associated brain
disorders, such as Parkinson’s disease and schizophrenia. However, the association between NURR1 defects and the
attention-deficit hyperactivity disorder (ADHD), a DA-associated brain disease characterized by hyperactivity,
impulsivity and inattention, has never been demonstrated. To date, a comprehensive murine model of ADHD truly
reflecting the whole complex human psychiatric disorder still does not exist. NURR1-knockout (NURR1-KO) mice have
been reported to exhibit increased spontaneous locomotor activity, but their complete characterization is still lacking.
In the present study a wide-ranging test battery was used to perform a comprehensive analysis of the behavioral
phenotype of the male NURR1-KO mice. As a result, their hyperactive phenotype was confirmed, while their impulsive
behavior was reported for the first time. On the other hand, no anxiety and alterations in motor coordination,
sociability and memory were observed. Also, the number of mDA expressing tyrosine hydroxylase, a rate-limiting
enzyme of catecholamines biosynthesis, and DA level in brain were not impaired in NURR1-KO mice. Finally,
hyperactivity has been shown to be recovered by treatment with methylphenidate, the first line psychostimulant drug
used for ADHD. Overall, our study suggests that the NURR1 deficient male mouse may be a satisfactory model to study
some ADHD behavioral phenotypes and to test the clinical efficacy of potential therapeutic agents.
Introduction
The nuclear receptor related 1 protein (NURR1, also
called NR4A2) is an orphan member of the steroid hor-
mone receptor family. It is a transcription factor essential
for the development and functioning of the dopaminergic
circuitry, particularly of midbrain dopaminergic neurons
(mDA). NURR1 is required for mDA generation, as its
ablation leads to their full agenesis1,2. It also plays a cri-
tical role in the migration and target area innervation of
differentiating mDA in the striatum3. In mature mDA,
NURR1 regulates genes of the dopamine (DA) signaling
pathway, including tyrosine hydroxylase (TH), DA trans-
porter 1 (DAT1), and vesicular monoamine transporter 2
(VMAT2)2,4,5. Finally, NURR1 exerts an anti-
inflammatory function in microglia, which protects
mDA from inflammation-induced death6,7. Given its
crucial functions, altered NURR1 expression is implicated
in DA-associated brain disorders, including Parkinson’s
disease (PD)8,9 and schizophrenia10,11.
ADHD is an heterogeneous developmental brain dis-
order, which affects children but often leads to adverse
consequences in adulthood, including drug abuse, delin-
quency, anxiety, depression, and social rejection12,13. It is
characterized by three main symptoms, namely hyper-
activity, impulsivity and inattention. Methylphenidate
(MPH), with a history of use spanning ~5 decades, is the
first line psychostimulant treatment for ADHD. MPH
enhance DA transmission through multiple actions,
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including blockade of the DA reuptake transporter and
amplification of the DA response duration14. Overall,
changes in catecholaminergic tone induced by the chronic
treatment of MPH lead to an improvement of the ADHD
symptoms, although not without side effects, such as
fatigue, nausea, and loss of appetite15.
It is generally accepted that ADHD has a strong genetic
component13, although genome-wide association studies
(GWASs) published to date are far from being conclusive,
mostly due to their small sample size16,17. Single nucleo-
tide polymorphisms in the NURR1 gene have been stu-
died in humans ADHD18. However, the association
between NURR1 polymorphism and gene expression has
been only found in in vitro experiments and not directly
in human ADHD18. Furthermore, the constitutive dele-
tion of NURR1 in mice have been reported to increase
spontaneous locomotor activity, a phenotype character-
istic of the ADHD symptomatology19–22. However, it is
still not clear whether the NURR1-knockout (NURR1-
KO) mice can be considered as a comprehensive model of
ADHD. Ideally, a comprehensive animal model should (I)
mimic the fundamental behavioral characteristics of
ADHD (face validity), (II) involve a similar pathophysio-
logical mechanism (construct validity), and (III) predict
responses to medications that could be used in ADHD
treatment (predictive validity). To date, hyperactivity is
still the only ADHD-like symptom described in NURR1-
KO mice. Impulsivity has never been examined, while
attention has been evaluated in a single study, which did
not highlight an altered behavior23.
Although brain abnormalities, especially in the regions
of basal ganglia, prefrontal cortex, and cerebellum, have
been documented in patients with ADHD24,25, the exact
pathogenesis of the disease remains elusive. A deeper
knowledge of ADHD neuroanatomy is necessary to
improve treatments, and reliable animal models are cru-
cial to achieve it. Besides NURR1-KO mice, some murine
models have been proposed as ADHD models, mostly
based on targeting genes involved in DA transmission26,27.
Here we examined the effects of the constitutive dele-
tion of NURR1 on the behavior and the number of TH-
expressing mDA of adult male mice. We focused on
locomotor activity, and impulsivity, but for an exhaustive
characterization we also evaluated motor coordination,
anxiety, sociability and memory. Finally, we examined
whether an altered behavioral phenotype could be
recovered following the exposition to human pharmaco-
logical doses of MPH.
Materials and methods
Animals
Three to five months old male NURR1-knockout mice
(NURR1-KO, n= 64) and their wild-type (WT, n= 68)
littermates were used for all experimental paradigms (see
Supplementary Materials, Table S1). Specifically, one
cohort of 9 WT and 7 NURR1-KO untreated mice
underwent the behavioral tests. At the end of the beha-
vioral tests, these mice were sacrificed to perform the
histological procedures. A second cohort of 7 WT and 4
NURR1-KO untreated mice were used for biomolecular
analysis. A third cohort of 6 WT and 10 NURR1-KO were
used for blood pressure, heart rate and DA measurement
in brain and plasma. A fourth and fifth cohort comprising
42 WT and 47 NURR1-KO mice were used for methyl-
phenidate experiments. The NURR1-KO mice were
obtained from Prof. Orla M. Conneely, Baylor College of
Medicine, Houston, USA. Since homozygous NURR1-KO
mice die within 12 h (h) after birth2,28, heterozygous mice
were used. Their genotype were confirmed by means of
polymerase chain reaction (PCR)28. All experimental
procedures were carried out at NICO, approved by the
Ethical Committee of the University of Torino and
authorized by the Italian Ministry of Health (authoriza-
tion number: 56/2017-PR). The experiments have been
carried out in accordance with the European Commu-
nities Parliament and Council Directives of 24 November
1986 (86/609/EEC) and 22 September 2010 (2010/63/EU).
Mice were housed with a 12 h light/dark cycle and free
access to food/water. Adequate measures were taken to
minimize pain and discomfort.
Behavioral tests
The WT and NURR1-KO animals underwent the
behavioral tests always during the light phase of the cycle,
leaving at least a week of break between tests. The
experiments were performed under dim white light con-
ditions (2 lux). At the end of each trial, the equipment
were accurately cleaned with ethanol 2% and water.
Where needed (i.e. open field; OF, elevated plus maze;
EPM, Morris water maze, three chamber sociability),
behavioral procedures were video-recorded and scored by
an individual blind to the genotype of the mouse. Data
were analyzed using Ethovision XT9 video track system
(Noldus Information Technology, Wageningen, The
Netherlands).
Open field test
Locomotor activity was investigated by means of the
Open field (OF) test. On test day, mice were transported
to the testing room and left undisturbed for 1 h before
testing. Each animal was placed in the corner of the arena
(50 × 50 × 50 cm) for 1 h. Total and 10-min bins distance
traveled, velocity and time spent in the central area (25 ×
25 cm) were video-recorded.
Cliff avoidance reaction test
Impulsivity was investigated by means of Cliff avoidance
reaction (CAR) test. On test day, mice were transported to
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the testing room and left undisturbed for 1 h before
testing. CAR was assessed27 using a round wooden plat-
form (diameter 20 cm), supported by a rod (height 50 cm).
The platform was secured so that the movement of the
animal did not affect it. The floor below the platform was
carpeted to prevent injury in case of a fall. The test was
initiated by gently placing an animal on a platform such
that the forelimbs approached its edge. Mice which fell
from platforms were immediately and gently placed back
on the platforms, and the test was continued until 1 h had
elapsed. Mice, which did not fall from platforms, were
tested for the same time period. The number of the mice
which fell from platforms and the time of fell have been
recorded and reported as percentage of the number of
tested mice and time course of CAR impairment,
respectively.
Rota-rod test
Motor performance and coordination were investigated
by means of rota-rod test. Mice were tested for three
consecutive days. In each day, after a 2 min (min) training
session at a constant speed (4 rpm), the mice received
three test sessions (T) in which the rod (Mouse Rota‐Rod,
Ugo Basile Biological Research Apparatus, Comerio, Italy)
accelerated continuously from 4 to 65 rpm over 350 s 29.
The latency to fall off the rod was recorded.
Elevated plus maze test
Anxiety-like behavior was investigated by means of
Elevated plus maze (EPM) test. On test day, mice were
transported to the testing room and left undisturbed for
1 h before testing. The EPM test apparatus was a plus-
cross shaped constructed from gray forex raised 60 cm
above the floor. It comprised two open arms (30 × 5 ×
0.20 cm) and two closed arms (30 × 5 × 15 cm walls) ori-
ginating from a central platform (5 × 5 cm). At the
beginning of each trial each animal was gently placed in
the center of the plus maze, facing an open arm and it was
allowed to explore the maze for 5 min30. The number of
entries in either open and closed arms and their respective
cumulative time spent was video-recorded and reported
as a frequency of entries and time spent in the open arms.
An animal was considered to have entered an arm of the
plus maze when all four paws had left the central
platform.
Morris water maze test
Spatial learning and memory of mice were investigated
by means of Morris water maze test (see Supplementary
Materials)31–33.
Three-chambered sociability test
On test day, mice were transported to the testing room
and left undisturbed for 1 h before testing. The test was
designed as previously described34,35 (see Supplementary
Materials).
Histological procedures
Seven NURR1-KO and nine WT littermates mice were
deeply anesthetized (ketamine 200mg/kg, xylazine 50mg/
kg) and trans-cardially perfused with 4% paraformalde-
hyde in 0.12M phosphate buffer, pH 7.2–7.4. The brains
were removed and immersed in the same fixative at 4 °C
for 24 h and then cryo-protected in 30% sucrose in 0.12M
phosphate buffer. Brains were frozen and serially cut by a
cryostat in 30 µm-thick coronal sections collected in
phosphate buffered saline (PBS). In order to detect tyr-
osine hydroxylase (TH) mDA neurons, slices were incu-
bated overnight at 4 °C with the monoclonal anti-mouse
TH (22941, Immunostar, Hudson, WI, USA) diluted
1:1000 in PBS with 0.25% Triton X-100 and 1.5% normal
goat serum. Immunohistochemical reactions were per-
formed by the avidin–biotin–peroxidase method (Vec-
tastain ABC Elite kit; Vector Laboratories, Burlingame,
CA, USA) and revealed using 3,3′-diaminobenzidine (3%
in Tris–HCl) as chromogen. Images for morphometric
analysis were acquired by means of the Nikon Eclipse
E600 microscope equipped with the Neurolucida system
(Micro Bright Field, Williston, VT, USA) and analyzed by
means of the ImageJ software (http://rsbweb.nih.gov/ij/
index.html). TH positive (+ ) cell number (cell number/
mm2) in the whole substantia nigra (SN) and ventral
tegmental area (VTA) (Bregma −2.92 mm, Interaural
0.88; Bregma −3.88 mm, Interaural −0.08) were quanti-
fied. At least three sections for animal were evaluated.
Biomolecular analysis
Four NURR1-KO and seven WT littermates mice were
euthanized by inhalation of isoflurane and brains were
removed. The brain areas (i.e. SN and VTA) were
manually dissected from 300 µm-thick coronal sections
cutter by vibratome (Bregma −2.92 mm, Interaural 0.88;
Bregma −3.88 mm, Interaural −0.08). All samples were
rapidly frozen in 2-methylbutane in dry ice and total RNA
was isolated by extraction with the Pure Link RNA Mini
Kit (Thermo Fisher Scientific, US) according to the
manufacturer’s instructions. Total RNA was reverse-
transcribed to complementary DNA (cDNA) at a final
concentration of 20 ng/μl using the High Capacity Kit
(Thermos Fisher Scientific, Waltham, MA, USA). Gene
expression analysis was performed by real-time PCR using
Applied Biosystems’ TaqMan gene expression products
(Thermos Fisher Scientific, Waltham, MA, USA). Tran-
scriptional expression was normalized using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as
reference gene. For primers and probes, Applied Biosys-
tems’ TaqMan® Assay-on-demand-TM gene expression
products were used (GAPDH; Mm99999915_g1, TH;
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Mm00447557_m1). Expression levels of target genes were
calculated by the normalized comparative cycle threshold
(Ct) method (2-ΔCt).
DA isolation and measurement
Ten NURR1-KO and six WT littermates mice were
euthanized by inhalation of isoflurane and brains were
removed and blood was collected into EDTA tubes. The
brains were rapidly frozen in 2-methylbutane in dry ice.
Blood samples were centrifuged 10min at 3000 G at 4 °C.
The plasma was removed and rapidly frozen in 2-
methylbutane in dry ice. Brains and plasma were stored
at −80 °C until use.
DA-1,1,2,2-d4 hydrochloride, trifluoroacetic acid and
tetrahydrofuran for liquid chromatography were pur-
chased from Sigma-Aldrich Corporation (Milan, Italy).
Acetonitrile (HPLC grade) was purchased from VWR
(Milan, Italy). HPLC-grade water was produced by a Milli-
DI system coupled with a Synergy 185 system by Millipore
(Milan, Italy). Previously weighted brain samples were
frozen in liquid nitrogen, sonicated for 1 min, recon-
stituted in 1mL of water and sonicated for another min.
The calibration curve of DA was established in the con-
centration range of 300–100,000 ng/mL. Five hundred
microliter plasma or brain samples were extracted by
protein precipitation using 1ml of acetonitrile/2-propa-
nol. Each sample was vortexed for at least 15 s and then
centrifuged at 12,000 rpm for 10min. The eluates were
evaporated with the Eppendorf AG Concentrator Plus
(Eppendorf AG, Hamburg, Germany). The extracted
sample was reconstituted with 250 μL of 97% of water
(0.1% trifluoroacetic acid)/acetonitrile (90/10) and 3% of
tetrahydrofuran and transferred to an injection vial.
Chromatographic separation was performed at 35 °C,
using a column oven, on a C18 reverse-phase column
(LiChrocart 250-4 Lichrospher 100RP-18 5 um, VWR,
Germany), protected by a Security Guard (VWR) pre-
column. The mobile phase was composed 97% of water
(0.1% trifluoroacetic acid)/acetonitrile (90/10) and 3%
of tetrahydrofuran. The flow rate was set at 1 mL/min.
DA plasma concentrations were reported as ng/mL,
instead brain amount were converted in ng/mg of tissue
weight.
Methylphenidate administration
NURR1-KO and WT littermates were administered a
saline solution (vehicle, 0.9% NaCl) of Methylphenidate
(MPH, racemic mixture, Sigma-Aldrich, St. Louis, MO) or
saline alone (0.9% NaCl, vehicle) by oral gavage using a
feeding needle (Fisher Scientific, Pittsburgh, PA) (Italian
Ministry of Health authorization number: SP/005). MPH
was administered at 0.75 mg/kg dose 1 h before behavioral
test as reported in ref. 36. This oral dose used has been
demonstrated to produces serum levels of MPH equiva-
lent to those seen in clinically treated humans36. We did
not withhold food prior to the gavage. Mice were not
anesthetized during the gavage procedure. To avoid
confounding results due to the double administration of
MPH, male NURR1-KO and WT mice never tested before
for behavioral analysis and never treated before with MPH
were treated with the drug or vehicle and randomized to
underwent OF or CAR test as indicated above. Specifi-
cally, 13 WT treated with vehicle, 14 NURR1-KO treated
with vehicle, nine WT treated with MPH, 10 NURR1-KO
treated with MPH were tested in the OF, whereas 11 WT
treated with vehicle, 13 NURR1-KO treated with vehicle,
nine WT treated with MPH, 10 treated with NURR1-KO
MPH tested in the CAR (Supplementary Materials,
Table S1).
Statistic
Power analysis has not been performed, due to the
several outcomes that we planned to analyze in this
study. Continuous data were presented as medians and
ranges. Normality of distribution was assessed by the
Shapiro-Wilk test and homogeneity of variance with
Levene test. Fisher’s exact test was used to compare the
number of fallen at the CAR test between groups. Two-
tailed t-test and Mann–Whitney U test were used
to compare continuous data between groups, as appro-
priate. Linear mixed effects models (LMM) were
used to compare longitudinal data between groups.
Kruskal–Wallis test with Dunn’s post hoc test was used
to compare the travelled distance at the OF test after
MPH treatment between groups. P values were adjusted
for multiple comparisons using the Benjamini–Hochberg
method to control the false discovery rate (FDR).
Statistical significance was considered at p values < 0.05.
All analyses were carried out using R version 3.5.1
(www.r-project.org).
Results
NURR1-KO mice exhibit hyperactivity and impulsivity
NURR1-KO mice developed normally with no major
differences in body weights (Fig. 1a, Mann–Whitney U
test, p= 0.07). Also, the systolic blood pressure and the
heart rate were measured in WT and NURR1-KO mice
highlighting no difference between genotypes (see Sup-
plementary Materials, Figure S1A-B, Mann–Whitney U
test, p= 0.44 for systolic blood pressure, p= 0.44 for
heart rate). The spontaneous locomotor activity was
measured by the OF test, evaluating the total distance
traveled and the velocity. When placed in a novel open
field, NURR1-KO mice resulted significantly more active
compared to their WT littermates (Fig. 1b, t-test, p=
0.002; Fig. 1c, t-test, p= 0.01). The analysis revealed that
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locomotor activity is significantly affected by both geno-
type and time (Fig. 1d). Particularly, in the 10-min bins
analysis, the distance travelled was overall greater in
NURR1-KO mice compared to WT mice (LMM, p=
0.0006), while it significantly decreased over time in both
groups (LMM, p= 0.0001). The analysis of the distance
travelled in the center of the OF did not highlight an
anxiety-like behavior of the NURR1-KO mice (Fig. 1e, t-
test, p= 0.25).
The CAR test was performed to evaluate the impulsivity
(Fig. 1f–g). As a result, 85.7% (six out of seven) of the
NURR1-KO mice fell from platforms during the 60 min
observation against the 11.1% (one out of nine) of the WT
mice, thus showing an impulsive behavior (Fig. 1f, Fisher
exact test, p < 0.0001). In addition, the time course of CAR
impairment was reported indicating that about the totality
(85.7%) of the NURR1-KO mice dropped from the plat-
forms within 30min (Fig. 1g).
Fig. 1 NURR1-KO mice show an increased locomotor activity and impulsivity. a Both WT (n= 9) and NURR1-KO (n= 7) mice were weighted
before the tests. No major differences were detected in body weight between WT and NURR1-KO mice (Mann–Whitney U test, p= 0.07). Both WT (n
= 9) and NURR1-KO (n= 7) mice were tested in the open field (OF, b–e) and cliff avoidance reaction test (CAR, f-g). b, c The OF analysis disclosed
that NURR1-KO mice showed an increased distance travelled (t-test, p= 0.002) and velocity (t-test, p= 0.01) in comparison to their WT littermates.
d The line plot shows distance moved (cm) as a function of 10-min bins, and the bar plot depicts the mean distance traveled (cm) per bin. Analysis
revealed that genotype conditions (LMM, p= 0.0006) and time (LMM, p= 0.0001) significantly influences locomotor activity. e In the same behavioral
test, NURR1-KO mice did not show an anxious phenotype indicated by the distance travelled in center compared with their WT littermates (t-test, p
= 0.25). f The analysis of CAR test in WT and NURR1-KO mice displayed that the 85.7% of the NURR1-KO mice fell from platforms (gray box) during
the 60 min observation against to the 11.1% of WT (Fisher exact test, p < 0.0001). g Time course of CAR impairment in WT and NURR1-KO mice was
reported and about the totality (85.7%) of the NURR1-KO mice dropped from the platforms within 30 min
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NURR1-KO mice do not show alterations in motor
performance and coordination
Motor coordination was evaluated using the accelerat-
ing rota-rod test (Fig. 2a, b). As demonstrated by the
comparison of the latency to fall in the first trial of the
first day (T1 DAY1) between the two groups, WT and
NURR1-KO mice exhibited similar basal motor coordi-
nation (Fig. 2a, T1 Day 1). Subsequently, they both
showed a significant improvement over days (LMM, p <
0.0001), independently from genotype (LMM, p= 0.47).
Also the total latency during the 3 days of trials did not
differ between the two groups of mice (Fig. 2b, t-test, p=
0.51).
NURR1-KO mice do not show an anxiety-like behavior
The EPM test was executed to confirm the absence of an
anxiety-like behavior in NURR1-KO mice, suggested by the
OF test (Fig. 1e). The frequency of entries (Fig. 2c,
t-test, p= 0.16) and the time spent (Fig. 2d, Mann–Whitney
U test, p= 0.34) in the open arms was similar in NURR1-
KO mice and their WT littermates. Also the number of
total entries did not differ between the two groups, indi-
cating that the test was well-conducted (Fig. 3e, t-test,
p= 0.66).
NURR1-KO mice do not show a defect in spatial memory
and learning
Spatial memory was tested by means of the Morris water
maze (Fig. 3a–e). During the first trial of the first day (when
the mice knew anything about the spatial location of the
platform) there was no difference in the swimming velocity
between groups (Fig. 3a, t-test, p= 0.63), suggesting normal
vision, locomotor skills, and motivation in NURR1-KO
animals. The acquisition phase of the test (Fig. 3b, days 1–4)
served to assess the ability of the mice to acquire spatial
information and learn the position of the hidden platform,
which was the same each day. During this phase, the escape
latency significantly decreased over time (LMM, p < 0.0001)
without differences between genotypes (LMM, p= 0.99),
indicating that both groups had the same spatial learning
potential. On the fifth day, the platform was removed and
all mice were tested for the ability to remember its previous
Fig. 2 NURR1-KO mice do not show alteration in motor performance and coordination and anxiety-like behavior Both WT (n= 9) and
NURR1-KO (n= 7) mice were tested on the rota-rod (a, b) and in the elevated plus maze (EPM) test for 5 min (c–e). a The analysis revealed that time
conditions (LMM, p < 0.0001) but not genotype (LMM, p= 0.47) significantly influences motor performance. b No differences were detected in the
total latency during the 3 days of trials (t-test, p= 0.51). c, d NURR1-KO did not reveal anxiety levels higher than WT mice analyzing the frequency of
the entries in the open arm (c t-test, p= 0.16) and the percentage of the time spent in the open arm (d Mann–Whitney U test, p= 0.34). e No
differences were detected also in the number of total entries (t-test, p= 0.66)
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position during a single probe trial (Fig. 3c–e). The memory
retention, defined as the accuracy ratio (AR; time spent in
the target quadrant multiplied by 3 and divided by the time
spent in the others three quadrants), was significantly lower
for the NURR1-KO mice compared to their WT littermates
(Fig. 3c, t-test, p= 0.002). In particular, unlike WT mice
which preferentially travelled in the target quadrant,
NURR1-KO mice spent approximately the same time in
each quadrant (median AR= 1.09). In addition, the latency
to reach the position of the removed platform during the
probe trial was similar for the two groups of mice (Fig. 3d,
Mann–Whitney U test, p= 0.11), meaning that the cap-
ability to reach the target is not altered in the NURR1-KO
mice. These findings led us to measure the path length after
Fig. 3 NURR1-KO mice do not show a defect in learning and memory. Both WT (n= 9) and NURR1-KO (n= 7) were tested in the Morris water
maze (a–e) and three chamber maze test (f, g). a The basal level of the swimming velocity was not different between groups (t-test, p= 0.63). b Mice
improved their performance across days without differences between genotypes. The analysis revealed that time conditions (LMM, p < 0.0001) but
not genotype (LMM, p= 0.99) significantly influences spatial learning and memory. c–e During the probe trial NURR1-KO mice showed a reduce
accuracy ratio (AR) in comparison to their WT littermates (c) (t-test, p= 0.002) without differences in the latency to reach the target quadrant (d)
(Mann–Whitney U test, p= 0.11). e Measures of the total distance travelled (cm) after they reached the target zone in the probe trial showed longer
path length outside the target zone (Q1, Q2, Q3) in NURR1-KO mice compared to WT mice (t-test, p= 0.03). f Mice displayed sociability, defined as
spending more time sniffing the mouse than sniffing the object (t-test, WT: p < 0.0001, NURR1-KO: p= 0.03). g NURR1-KO mice do not show
impairment in social memory spending more time sniffing the novel mouse than sniffing the familial one as WT (t-test, WT: p= 0.001, NURR1-KO:
p= 0.01)
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Fig. 4 NURR1-KO mice do not show a deficit of the mDA TH+ neurons and DA levels. Representative images of coronal brain sections of WT
(a–c) and NURR1-KO (d–f) mice stained with anti-TH antibody. The sections highlight the substantia nigra (SN) (a, b, d, e) and ventral tegmental area
(VTA) (a, c, d, f) regions as indicated by the black box. Calibration bars, 250 µm. g, h Quantitative analysis of the TH+ cell number in SN (g) and VTA
(h) of WT (n= 9) and NURR1-KO (n= 7) mice disclosed no differences between genotypes (t-test, in SN p= 0.49; in VTA p= 0.12). i, l Also the real-
time RT-PCR analysis revealed that the gene expression level of TH in SN (i) and VTA (l) was not different between WT (n= 7) and NURR1-KO (n= 4)
(t-test, in SN p= 0.92; in VTA p= 0.11). m, n DA quantification in brain (m) and in plasma (n) disclosed no differences between WT (n= 6) and
NURR1-KO (n= 10) mice (t-test, in brain p= 0.64; in plasma p= 0.17)
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Fig. 5 (See legend on next page.)
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mice reached the target zone. An increased path length
outside the target zone (Q1+Q2+Q3), after reaching the
original location of the platform, would suggest an attempt
to find a new location of the platform and thus an increased
behavioral flexibility. On the contrary, longer path length in
the target zone (QT) would suggest a persistency, possibly
related to an increased anxiety32. Here, NURR1-KO mice
displayed a significantly longer path length outside the
target zone compared with their WT littermates (Fig. 3e, t-
test, p= 0.03).
Finally, mice underwent the reversal task (Fig. 3b, days
6–8). On day 6 the platform location was changed and the
acquisition of a new memory was tested for three days.
NURR1-KO mice showed a shorter latency to find the
new platform compared to WT, especially in the sixth day
(LMM, time effect: p < 0.0001, genotype effect: p= 0.06),
further confirming their increased behavioral flexibility.
NURR1-KO mice do not show a defect in social behavior
and memory
Social behavior and social memory were evaluated using
the three chamber sociability test (Fig. 3f–g). The analysis
during the habituation phase did not highlight any innate
preference for a chamber in either mice group (data not
shown). Both groups displayed social behavior, defined as
spending more time sniffing the mouse than sniffing the
object (Fig. 3f, t-test, WT: p < 0.0001, NURR1-KO: p=
0.03). Furthermore, they exhibit a similar social memory,
as they both spent more time sniffing the novel mouse
than the familial one (Fig. 3g, t-test, WT: p= 0.001,
NURR1-KO: p= 0.01).
NURR1-KO mice do not show a deficit of the mDA TH+
neurons number and DA levels
NURR1 has a crucial role in controlling the functioning
of the mDA cells, which modulate locomotion and
impulsive behavior. mDA TH+ cells were thus counted
in the SN and VTA of WT and NURR1-KO mice
(Fig. 4a–f). No differences emerged between genotypes in
both SN (Fig. 4g, t-test, p= 0.49) and VTA (Fig. 4h, t-test,
p= 0.12). Real-time RT-PCR analysis confirmed these
data, as the gene expression level of TH in both SN
(Fig. 4i, t-test, p= 0.92) and VTA (Fig. 4l, t-test, p= 0.11)
was not significantly different between genotypes. Also,
the analysis of DA levels in brain (Fig. 4m, t-test, p= 0.64)
and plasma (Fig. 4n, t-test, p= 0.17) revealed no differ-
ences between genotypes.
MPH rescues hyperactivity but not impulsivity of NURR1-
KO mice
The effects of MPH treatment on locomotor activity
and impulsive behavior was examined in a separate cohort
of mice. WT and NURR1-KO mice, treated with vehicle
(0.9% NaCl) or MPH (0.75 mg/kg), underwent OF or CAR
tests 1 h after drug/vehicle administration (Fig. 5).
NURR1-KO mice treated with MPH showed a decreased
locomotor activity in comparison to their NURR1-KO
vehicle treated littermates, in terms of both distance tra-
velled (Fig. 5a, Kruskal–Wallis with Dunn’s post hoc test,
df= 3, p= 0.03) and velocity (Fig. 5b, Kruskal–Wallis
with Dunn’s post hoc test, df= 3, p= 0.03) at the OF test.
Particularly, NURR1-KO mice treated with MPH per-
formed similarly to WT mice treated with vehicle
(Kruskal–Wallis with Dunn’s post hoc test, df= 3, dis-
tance travelled: p= 0.33, velocity: p= 0.29) or MPH
(Kruskal–Wallis with Dunn’s post hoc test, df= 3, dis-
tance travelled: p= 0.39, velocity: p= 0.38). On the other
hand, the MPH treatment did not rescue the impulsive
behavior of the NURR1-KO mice at the CAR test. In fact,
80% (8 out of 10) of the NURR1-KO mice treated with
MPH fell from the platform compared to 77% (10 out of
13) of their littermates with the same genotype treated
with vehicle (Fig. 5c, Fisher exact test, p= 1). Meanwhile,
33.3% (three out of nine) of the WT mice treated with
MPH and 18% (two out of 11) of the WT mice treated
with vehicle fell from the platform, indicating no
treatment-effects on impulsivity of WT mice.
Discussion
The transcription factor NURR1 regulates genes of the
DA signaling pathway2,4,5 and is essential for the mDA
development7,37. This is probably due to its ability to not
(see figure on previous page)
Fig. 5 MPH rescues the altered locomotor activity of NURR1-KO mice but not their impulsive behavior. Both WT and NURR1-KO mice treated
with vehicle (0.9% NaCl) or MPH (0.75 mg/kg) 1 h before were tested in the open field (OF, a, b) or cliff avoidance reaction (CAR, c, d) for 1 h. a, b The
analysis disclosed that NURR1-KO mice treated with MPH show a rescue in their altered locomotor activity, in terms of distance travelled (a)
(Kruskal–Wallis with Dunn’s post hoc test, df= 3, p= 0.03) and velocity (b) (Kruskal–Wallis with Dunn’s post hoc test, p < 0.0001, df= 3, p= 0.03). The
NURR1-KO mice treated with MPH perform similarly to WT mice treated with vehicle and MPH (Kruskal–Wallis with Dunn’s post hoc test, vehicle
distance travelled: p= 0.33, velocity: p= 0.29; MPH distance travelled: p= 0.39, velocity: p= 0.38). Number of mice tested for OF: 13 WT vehicle, 14
NURR1-KO vehicle, 9 WT MPH, 10 NURR1-KO MPH. c The analysis of CAR test displayed that NURR1-KO mice treated with MPH did not show a rescue
in their impulsive behavior (Fisher exact test, p= 1). Gray box indicates the percentage of mice which fell from the platform. d Also the time course of
CAR impairment in WT and NURR1-KO mice after the MPH administration was reported. Number of mice tested for CAR 11 WT vehicle, 13 NURR1-KO
vehicle, 9 WT MPH, 10 NURR1-KO MPH
Montarolo et al. Translational Psychiatry           (2019) 9:207 Page 10 of 13
only regulate genes of the DA signaling pathway2,4,5, but
also to protect mDA against inflammation-induced
damage6,7,37. Given its functions, it play a critical role in
DA-associated brain disorders, such as schizophrenia and
PD8–11.
Animal models able to recapitulate the key phenotypes
of neurological disorders are crucial to understand the
biological basis of the diseases and to test the clinical
efficacy of potential therapeutic agents, as reported in
their face, construct and predictive validity. The NURR1-
KO mouse was suggested as a model for schizophrenia21
and PD20, but further studies highlighted that it only
exhibits a restricted behavioral phenotype of these dis-
eases38. Given its increased spontaneous locomotor
activity19–22 the NURR1-KO mouse could be proposed as
well as a model of ADHD. However, to date a complete
characterization of this model is still lacking.
In the present study, we performed a comprehensive
analysis of the behavioral phenotype of the NURR1-KO
mice. The use of a wide-ranging test battery allowed us to
demonstrate the presence of two main ADHD symptoms,
in the absence of other non-specific behavioral alterations.
First, we confirmed their increased spontaneous loco-
motor activity at the OF test in a novel environment. This
result is reasonably reliable, considering that this pheno-
type has been observed in three other independent
laboratories19–22 using three different NURR1-KO mod-
els1,2,39. Second, for the first time to our knowledge, we
reported an impulsive behavior in the NURR1-KO mice at
the CAR test. Third, we have not evaluated their atten-
tion. However, in previous studies, the NURR1-KO mice
did not exhibit an impairment in attention using the
multiple-choice visual discrimination and the latent
inhibition tests22,23. It is known that these tests require
long-term experimental procedures, including food/water
restriction, which are highly stressful and could affect the
attentional function of the animals40. Here, we tested only
male mice to avoid confounding results related to sex. It is
noteworthy that ADHD seems to affect more boys than
girls13 and that the behavioral problems of ADHD boys
seems to differ from those of ADHD girls41. Particularly,
the primary deficit in boys may be described as hyper-
activity and impulsiveness without attention problems
that instead affects the girls. Accordingly, our demon-
stration that NURR1-KO mice show hyperactivity and
impulsivity without attention problems as reported by23
make it a valid model for ADHD (face validity).
Fourth, no alterations emerged in their motor coordi-
nation at the rota-rod test. This is in agreement with
reports highlighting no alterations in the performance of
adult (i.e. between 2 and 10 months of age) NURR1-KO
mice compared to their WT littermates20. On the con-
trary, the rota-rod performance have been demonstrated
to decrease in old NURR1-KO mice (i.e. from 15 months
of age), suggesting motor impairment as an elderly PD
defect. Fifth, we excluded an anxiety-like behavior at the
EPM test. Sixth, we corroborate previous data reporting
no abnormalities in spatial recognition memory and
learning and social interaction and recognition22 using
different experimental approach, such as Morris water
maze and three-chambered sociability test instead of T-
maze and Y-maze tests, respectively.
Besides performing behavioral tests, we also evaluated
the number of TH-expressing mDA and the TH tran-
script level in SN and VTA, obtaining no differences
between NURR1-KO and WT mice. On this matter,
contrasting results can be found in the literature.
According to our data, Jiang and Kummari found no
alterations in the number of TH-expressing mDA in the
SN of adult NURR1-KO mice20,42. On the contrary,
Vuillermot and colleagues reported a reduction of these
mDA in NURR1-KO mice of the same age23. Notably,
mice with a different genetic background were used. In
particular, in Jiang’s and our study NURR1-KO mice
created by Saucedo-Cardenas and colleagues2 were tested
at the same age20. Also, DA level of NURR1-KO mice
reveled no differences between genotypes. These data are
in contrast with previous results reporting a decreases
level of DA in whole brain19. However, they analyzed
younger mice with different genetic background19.
Finally, we found that acute treatment with MPH, a
stimulant drug currently used to correct the ADHD
symptoms, is able to partially restore the behavioral
phenotype of the NURR1-KO mice. Interestingly, MPH is
able to rescue the hyperactive behavior but not the
impulsive one. Considering that the treatment of psy-
chiatric diseases involves the chronic administration of
drugs, the results obtained from acute treatment can be
considered an excellent starting point. Overall, our study
suggests that the NURR1 deficient male mouse may be a
satisfactory model to study some behavioral phenotypes
such as hyperactivity and impulsivity characteristic of the
human hyperactive-impulsive subtypes of ADHD
according to the DSM-V. Various animal models, such as
the spontaneous hypertensive rats (SHR)43, the neonatal
6-hydroxydopamine (6-OHDA) rats44 and DAT-KO45
mice are useful tool to study at least in part the hetero-
geneous aspects of ADHD symptomatology and neuro-
biology. Notably, in these animal models the hyperactivity
and the impulsive/attentive defects are evaluated using
the OF and the multiple-choice visual discrimination and
latent inhibition tests, respectively. Here, we evaluated the
face validity of the NURR1-KO mice through assessing
the spontaneous activity in the OF and impulsivity in an
easier investigation such as CAR. Specifically, this well-
demonstrated impulsive behavior represent a suitable
model to study impulsivity without long experimental
training and food/water deprivation that could stress the
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animals. Although the NURR1-KO mouse model failed to
show inattention23, this does not make it any less valuable,
since in humans attention deficit seems to especially affect
girls while hyperactivity and impulsiveness affect boys the
most13,41.
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